Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury
- 1 January 2018
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 143, 361-375
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science funding of China (81703352, 81770825, 81622043, 81670768)
- Natural Science Funding of Zhejiang Province (LR16H310001, LR18H160003, LQ18B020004)
This publication has 45 references indexed in Scilit:
- Models and mechanisms of acute lung injury caused by direct insultsEuropean Journal of Cell Biology, 2012
- The Acute Respiratory Distress Syndrome: Pathogenesis and TreatmentAnnual Review of Pathology: Mechanisms of Disease, 2011
- Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studiesExpert Opinion on Drug Metabolism & Toxicology, 2011
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- MD-2–Dependent Pulmonary Immune Responses to Inhaled LipooligosaccharidesAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Crystal Structure of CD14 and Its Implications for Lipopolysaccharide SignalingJournal of Biological Chemistry, 2005
- The evolving role of natural products in drug discoveryNature Reviews Drug Discovery, 2005
- Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndromeThe Journal of Pathology, 2003
- Essential role of MD-2 in LPS responsiveness and TLR4 distributionNature Immunology, 2002
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000